Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
561-580 of 2,251 trials

Diffuse Large B-cell Lymphoma: Rituximab and Golcadomide Study

We are testing a new combination treatment for older frail patients with Diffuse Large B-cell non-Hodgkin Lymphoma. This study aims to see if it can improve outcomes without traditional chemotherapy.

Diffuse Large B-cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Menopausal Women with Breast Cancer: Prasterone Therapy

We are studying whether a vaginal treatment can improve urinary and vaginal symptoms in menopausal women with a history of breast cancer or those currently on hormone therapy. The goal is to see how this therapy affects their quality of life and overall wellbeing.

Breast CancerGenitourinary Syndrome of Menopause≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncologyUrology

Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

Dominant Optic Atrophy>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurologyOphthalmology

Recurrent Diverticulitis: MBK-01 Capsules

We are studying whether MBK-01, a new intestinal microbiota capsule, can help reduce episodes of recurrent diverticulitis. The trial will also assess its safety and find the best dosage for patients.

Acute Diverticulitis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesGastroenterology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementOncology

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Optimizing Drug Levels

We are studying how blood levels of heart failure medications affect patient health. This research may help improve treatment plans for individuals with heart failure.

Chronic Heart Failure with Reduced Ejection Fraction>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

AUTO1 Treatment for Pediatric Blood Cancers

We are studying the safety and early effectiveness of AUTO1 in children with relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma. This trial aims to see how well the treatment works and how it can be safely administered.

B-cell Acute Lymphoblastic LeukemiaAggressive Mature B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Suicidal Thoughts: Nitrous Oxide Treatment in Emergencies

We are studying whether inhaling a mix of nitrous oxide and oxygen can reduce suicidal thoughts in patients at emergency departments. The trial also looks at its effects on anxiety and depression symptoms over time.

Suicidal Thoughts≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Long-Term Safety Study of Ongoing Treatment with Study Drugs

We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.

Metastatic Breast CancerMetastatic Non-Small Cell Lung CancerHER2 Positive Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

MB-CART2019.1 Therapy for Pediatric B-Cell Neoplasms

We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.

Refractory or Recurrent B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Tourette Disorder: Serotonin and Impulsivity Study

We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.

Tourette Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry